DelveInsight’s, “Dry Eye Disease Pipeline Insight 2023” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the Dry Eye Disease pipeline landscape. It covers the Dry Eye Disease Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Dry Eye Disease Pipeline Report
DelveInsight’s Dry Eye Disease pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Dry Eye Disease treatment.
The leading companies working in the Dry Eye Disease market include Alcon, HanAll Biopharma, Ocular Therapeutix, Seinda Pharmaceutical, IVIEW Therapeutics, Novaliq GmbH, Kowa Company, Seikagaku Corporation, Aramis Biosciences, Dreamhawk Vision Biotech Inc., Taejoon Pharmaceutical, Quorum Innovations, Serentrix, Noveome, Allysta Pharmaceuticals, BRIM Biotechnology, Invirsa, and others.
Promising Dry Eye Disease Pipeline Therapies in the various stages of development include OK-101, SHJ002/Vehicle, TL-925, SY-201 Ophthalmic Solution 2.0%, K-161, Tivanisiran sodium ophthalmic solution, Oxervate, HU007, Restasis, Moisview Eye drop, Masked Ikervis, and others.
On May 2023, Dreamhawk Vision Biotech Inc. announced a study of Phase 2 Clinical Trials for SHJ002/Vehicle. The purpose of this study is to measure efficacy and safety with SHJ002 sterile ophthalmic solution compared to vehicles in participants with Dry Eye Disease (DED).
In June 2023, Okyo Pharma Ltd announced a study of Phase 2 Clinical Trials for OK-101. The objective of this study is to compare the safety and efficacy of OK-101 Ophthalmic Solution to a placebo for the treatment of the signs and symptoms of dry eye.
Request a sample and discover the recent advances in Dry Eye Disease Treatment Drugs @ Dry Eye Disease Pipeline Report
The Dry Eye Disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Dry Eye Disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Dry Eye Disease clinical trial landscape.
Dry Eye Disease Overview
Dry eye disease (DED), also known as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular suface inflammation and damage, and neuorsensory abnormalities.
Find out more about Dry Eye Disease Treatment Drugs @ Drugs for Dry Eye Disease Treatment
Dry Eye Disease Emerging Drugs Profile
AR-15512: Alcon
HL036: HanAll Biopharma
OTX-DED: Ocular Therapeutix
SY-201: Seinda Pharmaceutical
iVIEW 1001: IVIEW Therapeutics
Dry Eye Disease Pipeline Therapeutics Assessment
There are approx. 45+ key companies which are developing the therapies for Dry Eye Disease. The Dry Eye Disease companies which have their Dry Eye Disease drug candidates in the most advanced stage, i.e. phase III include, Alcon.
Learn more about the emerging Dry Eye Disease Pipeline Therapies @ Dry Eye Disease Clinical Trials Assessment
Scope of the Dry Eye Disease Pipeline Report
Coverage- Global
Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Dry Eye Disease Companies- Alcon, HanAll Biopharma, Ocular Therapeutix, Seinda Pharmaceutical, IVIEW Therapeutics, Novaliq GmbH, Kowa Company, Seikagaku Corporation, Aramis Biosciences, Dreamhawk Vision Biotech Inc., Taejoon Pharmaceutical, Quorum Innovations, Serentrix, Noveome, Allysta Pharmaceuticals, BRIM Biotechnology, Invirsa, and others.
Dry Eye Disease Pipeline Therapies- OK-101, SHJ002/Vehicle, TL-925, SY-201 Ophthalmic Solution 2.0%, K-161, Tivanisiran sodium ophthalmic solution, Oxervate, HU007, Restasis, Moisview Eye drop, Masked Ikervis, and others.
Dive deep into rich insights for new drugs for Dry Eye Disease Treatment, Visit @ Dry Eye Disease Market Drivers and Barriers, and Future Perspective
Table of Content
Introduction
Executive Summary
Dry Eye Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Dry Eye Disease– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
AR-15512: Alcon
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
OTX-DED: Ocular Therapeutix
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SY-201: Seinda Pharmaceutical
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Dry Eye Disease Key Companies
Dry Eye Disease Key Products
Dry Eye Disease- Unmet Needs
Dry Eye Disease- Market Drivers and Barriers
Dry Eye Disease- Future Perspectives and Conclusion
Dry Eye Disease Analyst Views
Dry Eye Disease Key Companies
Appendix
For further information on the Dry Eye Disease Pipeline therapeutics, reach out to Dry Eye Disease Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting